Can Prigrel be viable in anti-clotting market?

Published: 2008-06-23 06:31:00

Updated: 2008-06-23 06:31:00

Sanofi Aventis’s Plavix is truly far ahead of Korea generic markers in the domestic anti-clotting market in terms of market share, however, Chong Kun Dang Pharmaceutical is hoping to challenge its competitors with its chemically modified clopidogrel “Since Prigrel is more cost-effective than our ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK